logo
Menu
Innovation Observatory > Reports > Drugs > Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis

< Back

Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis

Drugs

Skin Disease, Burns and Wound Care

November 2017


Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking a specific process which allows the body’s immune cells (specifically T-cells) from attacking and damaging the skin. Risankizumab is currently being trialled in a range of diseases involving the immune system including Crohn’s disease, and psoriatic arthritis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Risankizumab for Plaque Psoriasis



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts
Get Alerts